AstraZeneca reported Q4 2025 sales of $15.50B, up 4% YoY. Adjusted EPS was $2.12. Cancer business accounted for 45% of sales.
AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported fourth-quarter 2025 sales of $15.50 billion, up 4% year over year (+2% at constant currency or cc), almost in line with the consensus of $15.49 billion.
The adjusted earnings were $2.12 per share, beat… [1891 chars]
Source: Benzinga | Published: 2026-02-10T17:32:49Z
Credit: Benzinga
